White contract and black pen on blue background to show NICE approves Pfizer's Ibrance in new combination for certain breast cancers

Roche and Spark Therapeutics’ merger cleared by CMA

The CMA has cleared Roche and Spark Therapeutics' merger paving the way for the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical...
Image of hands shaking on a blue background to show SMC recommends Roche’s Ocrevus for people with PPMS

Pfizer’s VYNDAQEL® (tafamidis) receives positive CHMP opinion

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...
Cartoon image of westminster with big ben, london eye, red telephone box and houses of parliament to show ABPI responds to General Election result

ABPI responds to General Election result

The ABPI has responded to the General Election result welcoming the news and saying that it is looking forward to working with the new...
Woman sat on hospital examination bed with doctor, equipment and scans to show Breast cancer blood test could help target treatment

Breast cancer blood test could help target treatment

A breast cancer blood test can help identify rare mutations in advanced breast cancer and may enable patients to access effective treatments more quickly...
Janssen presents initial results for BCMA CAR-T therapy

Janssen presents initial results for BCMA CAR-T therapy

Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early, deep and high responses in the treatment of relapsed or refractory multiple myeloma. The...
hands shaking in front of a contract being signed by a man and a woman to show Servier and UCL collaborate on immune-inflammatory disease treatments

Servier and UCL collaborate on immune-inflammatory disease treatments

Accelerating the discovery of new treatments for immune-inflammatory disease, including lupus and systemic sclerosis, is the focus of a new strategic research collaboration between...
Man and woman shaking hands to show Acquisition of Ashfield Pharmacovigilance from UDG Healthcare

Forendo and Novartis partner on novel chronic liver disease treatments

Forendo and Novartis are to partner on novel chronic liver disease treatments. Forendo Pharma, a clinical stage drug development company focusing on novel treatments...
Kite announces new Yescarta® data from pivotal ZUMA-1 trial

Kite announces new Yescarta® data from pivotal ZUMA-1 trial

Kite announces new Yescarta® data from pivotal ZUMA-1 trial. The new data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) showed that approximately...
Graphic of Scotland with the Scottish flag over the top to show AstraZeneca and MSD's Lynparza™ now available in Scotland

AstraZeneca and MSD’s Lynparza™ now available in Scotland

AstraZeneca and MSD's Lynparza™ is now available in Scotland as the companies announce that olaparib monotherapy is now accepted for use by the Scottish...
Science technology equipment showing Novartis highlights progress in R&D pipeline

Novartis highlights progress in R&D pipeline

Novartis is holding an investor event to provide a comprehensive overview of the company’s progress in advancing its R&D pipeline. Key highlights to be presented...

Latest articles

image of pharmacy shelves full of medicines to show New community pharmacy quality standard highlights prevention role

New community pharmacy quality standard highlights prevention role

A new community pharmacy quality standard published by NICE says that the teams have the potential to play a greater role in health promotion...
image of tablet, magnifying glass, pad, pen and cogs with graphs and flow charts to show NICE wants more data on histology independent cancer treatments

NICE wants more data on histology independent cancer treatments

The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
White contract and black pen on blue background to show NICE approves Pfizer's Ibrance in new combination for certain breast cancers

NICE approves Pfizer’s Ibrance in new combination for certain breast cancers

Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
black and white photo of Craig Bradley to show Key publications to impact the UK access environment in 2020

Key publications to impact the UK access environment in 2020

Craig Bradley, Commercial Lead Rare GI at Takeda, PM Society Chair & PM Society Market Access Interest Group Lead, looks at key publications to...
image of tablet, magnifying glass, pad, pen and cogs with graphs and flow charts to show NICE wants more data on histology independent cancer treatments

NICE wants more data on histology independent cancer treatments

The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
moving up the career ladder: Making a career move in pharma

Making a career move in pharma

If you feel that you have gone as far as you can in your current role, it could be time to make a career...
White contract and black pen on blue background to show NICE approves Pfizer's Ibrance in new combination for certain breast cancers

NICE approves Pfizer’s Ibrance in new combination for certain breast cancers

Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription